The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Dailiport 0.5 mg Prolonged-release hard capsules

0.5 milligram(s) Prolonged-release capsule, hard

Rowex LtdPA0711/294/001

Main Information

Trade NameDailiport 0.5 mg Prolonged-release hard capsules
Active SubstancesTacrolimus
Strength0.5 milligram(s)
Dosage FormProlonged-release capsule, hard
Licence HolderRowex Ltd
Licence NumberPA0711/294/001

Group Information

ATC CodeL04AD Calcineurin inhibitors
L04AD02 tacrolimus


Licence Issued17/01/2020
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See: Summary of Product Characteristics, section 4.2)
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back